Cartilage repair Glendale: when should your knee be examined?

What will the clinician check?

The clinician asks where it hurts and whether it swells, catches or gives way. Then the knee is watched while bending, walking and bearing weight.

A scan can show cartilage and the bone under it. The meniscus cushion and the ligaments that steady the knee are checked for damage.

Say what the knee feels like later that same day. Soreness after stairs may matter more than soreness while sitting.

Which warning signs need faster care?

Seek prompt care when fever comes with a hot, swollen knee. Sudden swelling after a hard injury also needs quick help.

A locked knee, weak leg or numb area isn't routine. Get care soon if the knee won't straighten or hold your weight.

How can recovery fit ordinary days?

Ask for written dates for driving, stairs, work and full weight. Those dates make the home plan much clearer.

Non-surgical care may allow normal walking after a clinic visit. A graft or two-operation cell repair can bring months of limits and planned rehab.

What if the soreness keeps returning?

At QC Kinetix, medical providers examine the sore joint and discuss regenerative treatments made from your blood. Concentrated platelet-rich plasma is the part holding extra platelets after separation.

Platelets are tiny blood pieces that help a clot form. Bring past care notes and ask what the treatment may mean for walking or stairs.

Sources

1. A JBJS evidence-based review of chondral lesions of the knee sets management by lesion size, location, limb alignment and rotation, and patient demand rather than by product: osteochondral autograft transfer is described as durable and predictable for smaller lesions (under 2 cm2) in young active patients, while lesions of 2 cm2 or more are typically treated with osteochondral allograft transplantation, particulated juvenile articular cartilage, or matrix-associated chondrocyte implantation, with favourable mid- and long-term results reported for allograft or MACI in large lesions of 3 cm2 or more.

   Dekker TJ, et al. — Chondral Lesions of the Knee: An Evidence-Based Approach.. J Bone Joint Surg Am, 2021. DOI: 10.2106/JBJS.20.01161.

2. FDA biologics licence BL 125603 (Vericel) describes MACI verbatim as "an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults." The licensed indication is a two-stage surgical implantation for full-thickness DEFECTS of the knee in adults. It is not an injection, it is not licensed for osteoarthritis, and it is not licensed for any joint other than the knee.

   U.S. Food and Drug Administration — MACI (autologous cultured chondrocytes on porcine collagen membrane). FDA, Center for Biologics Evaluation and Research, 2024.

3. In the SUMMIT randomised trial, 144 patients with at least one symptomatic Outerbridge grade III-IV knee defect of 3 cm2 or more (mean lesion 4.8 cm2, mean age 33.8) were randomised to MACI or microfracture. At two years, improvements in KOOS pain (37.0 to 82.5 versus 35.5 to 70.9) and function (14.9 to 60.9 versus 12.6 to 48.7) were significantly greater with MACI.

   Saris D, et al. — Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Two-Year Follow-up of a Prospective Randomized Trial.. Am J Sports Med, 2014. DOI: 10.1177/0363546514528093.

4. At 14 to 15 years, the Norwegian multicentre randomised trial of 80 patients with a single symptomatic femoral condyle cartilage defect found no significant difference between autologous chondrocyte implantation and microfracture on any clinical scoring system. There were 17 failures in the ACI group versus 13 after microfracture, and more total knee replacements had been needed after ACI (6 versus 3).

   Knutsen G, et al. — A Randomized Multicenter Trial Comparing Autologous Chondrocyte Implantation with Microfracture: Long-Term Follow-up at 14 to 15 Years.. J Bone Joint Surg Am, 2016. DOI: 10.2106/JBJS.15.01208.

5. The ACTIVE randomised trial assigned 390 patients aged 18-55 whose previous cartilage surgery had failed to autologous chondrocyte implantation or alternative surgical management. At five years there was NO evidence of a difference in Lysholm score (2.9 points, 95% CI -1.8 to 7.5; P = .46), about 55% were still experiencing benefit in the ACI arm, time to cessation of benefit was similar, and significantly more participants had a serious adverse event with ACI (P = .02). Previous marrow stimulation had a detrimental effect on ACI outcome.

   Snow M, et al. — A Randomized Trial of Autologous Chondrocyte Implantation Versus Alternative Forms of Surgical Cartilage Management in Patients With a Failed Primary Treatment for Chondral or Osteochondral Defects in the Knee.. Am J Sports Med, 2023. DOI: 10.1177/03635465221141907.

6. At ten years the same 390-patient ACTIVE trial found the ACI arm scored significantly higher on Lysholm (mean difference 7.3 points, 95% CI 2.5 to 12.1), while ten-year treatment failure rates were comparable at 29% versus 25% (HR 1.04). A sensitivity analysis accounting for later operations reduced the advantage to 3.8 points (95% CI -1.8 to 9.5). The five-year and ten-year readouts of the same trial point in different directions, which is why a single follow-up point should never be quoted alone.

   Snow M, et al. — Ten year follow-up of a randomized trial of autologous chondrocyte implantation versus alternative forms of surgical cartilage management in the knee.. Osteoarthritis Cartilage, 2026. DOI: 10.1016/j.joca.2026.03.112.